Key takeaways
- Immunotherapy combinations, adjuvant therapy, and HIF-2α inhibition have expanded treatment options in renal cell carcinoma.
- Non-clear cell RCC requires stronger clinical evidence and dedicated trials.
- Emerging biomarkers, radiotheranostics, antibody-drug conjugates, and cellular therapies represent important research directions.
- Translating scientific advances into equitable, personalized kidney cancer care requires multidisciplinary collaboration and locally relevant strategies.
In his opening address at VIRO 2026: Global Voices in Renal Oncology, organized by OncoDaily, Pedro Barata, Director of the Clinical Genitourinary Medical Oncology Research Program at University Hospitals Seidman Cancer Center and Associate Professor of Medicine at Case Western Reserve University, outlined the scientific and clinical challenges shaping the next phase of kidney cancer care.
The expansion of therapeutic options in renal cell carcinoma (RCC) has changed the nature of clinical decision-making. Immunotherapy combinations have transformed the management of advanced disease, adjuvant treatment has entered routine clinical practice, and hypoxia-inducible factor 2 alpha (HIF-2α) inhibition has introduced a new therapeutic approach.
Yet some of the most pressing questions in renal oncology today concern how, when, and for whom these advances should be used.
More Treatment Options, More Complex Clinical Decisions
As the number of available therapies increases, determining the optimal treatment sequence for individual patients becomes increasingly complex.
The introduction of immunotherapy into earlier stages of kidney cancer care raises questions about subsequent treatment selection, particularly for patients whose disease recurs following adjuvant therapy.
Managing treatment-related toxicity, overcoming therapeutic resistance, and preserving quality of life are equally important considerations.
“But more treatment options also bring more difficult questions. How should we select and sequence treatment for an individual patient? How do we manage toxicity while preserving quality of life? What should we do when disease recurs after adjuvant therapy?”
These questions also reinforce the importance of understanding disease biology, pathology, and the role of diagnostic tools in informing treatment decisions.
From localized and hereditary kidney cancer to high-risk and metastatic disease, multidisciplinary collaboration remains central to patient management.
Beyond Clear Cell Renal Cell Carcinoma
Progress in renal oncology has not been uniform across histological subtypes.
While much of the evidence informing contemporary RCC treatment comes from studies in clear cell disease, patients with papillary, chromophobe, translocation-associated, and other non-clear cell renal tumors continue to face important evidence gaps.
Dedicated clinical trials and a better understanding of the biological characteristics of these tumors remain priorities for the field.
Alongside these challenges, several areas of investigation could further reshape kidney cancer management:
- Circulating tumor DNA (ctDNA) and emerging biomarkers
- The microbiome and its relationship with treatment response
- HIF-2α inhibition
- Radiotheranostics and novel imaging approaches
- Antibody-drug conjugates (ADCs)
- Cellular therapies
These approaches are at different stages of clinical development, with ongoing research examining their potential roles in diagnosis, treatment selection, and disease management.
When Global Evidence Meets Local Reality
One of the less frequently addressed dimensions of therapeutic innovation is the environment in which it is implemented.
The availability of diagnostic technologies, access to systemic therapies, healthcare infrastructure, and socioeconomic circumstances can all influence how evidence translates into everyday clinical practice.
As Barata put it:
“The evidence may be global, but the implementation is always, always local.”
A treatment supported by clinical evidence may not be equally accessible across countries or even across institutions within the same healthcare system.
This makes locally relevant research and international collaboration particularly important in addressing disparities in renal oncology.
It also broadens the discussion beyond pharmacological interventions to include lifestyle medicine, social determinants of health, palliative care, and the experiences of patients living with kidney cancer.
Defining Progress in Renal Oncology
The next phase of kidney cancer research will need to address not only which therapies work, but which patients benefit from them, how they should be integrated into existing treatment strategies, and how those strategies can be implemented across different healthcare settings.
Such questions require contributions from medical oncologists, urologists, pathologists, radiation oncologists, scientists, palliative care specialists, and patient advocates.
Ultimately, progress in renal oncology should be measured not only by the development of new therapies, but also by our ability to translate scientific discoveries into more personalized, effective, and equitable patient care.
Written by Eliz Baloyan, MD, Features Writer and Editor at OncoDaily and CancerWorld
